Skip to main content

Table 6 Pathogenicity and persistent infection capacity comparison of E6/E7 variants/mutations

From: Study on the detection rate, genetic polymorphism, viral load, persistent infection capacity, and pathogenicity of human papillomavirus type 33

Variant/mutation

 

With

Without

Relative risk (95% CI)

p

E6 prototype

CIN3+

40

6

1.30 (1.11–1.52)

0.008

 

CIN2

15

6

1.07 (0.80–1.43)

0.676

 

CIN1

34

4

1.34 (1.15–1.56)

0.006

 

CIN + total

89

16

1.27 (1.11–1.45)

0.001

 

Persistent

48

14

1.30 (1.04–1.62)

0.025

A213C (K35N)

CIN3+

5

41

0.37 (0.16–0.88)

0.011

 

CIN2

3

18

0.49 (0.17–1.43)

0.148

 

CIN1

3

35

0.27 (0.09–0.82)

0.006

 

CIN + total

11

94

0.36 (0.19–0.66)

< 0.001

 

Persistent

11

51

0.49 (0.26–0.89)

0.013

A364C (N86H)

CIN3+

3

43

0.033 (0.11–1.03)

0.035

 

CIN2

3

18

0.72 (0.24–2.16)

0.55

 

CIN1

2

36

0.27 (0.07–1.07)

0.033

 

CIN + total

8

97

0.38 (0.19–0.81)

0.007

 

Persistent

7

55

0.46 (0.21–1.03)

0.046

A387C (K93N)

CIN3+

5

41

0.43 (0.18–1.02)

0.036

 

CIN2

3

18

0.56 (0.19–1.65)

0.26

 

CIN1

3

35

0.31 (0.10–0.95)

0.019

 

CIN + total

11

94

0.41 (0.22–0.76)

0.003

 

Persistent

10

52

0.49(0.26–0.94)

0.022

A446G (Q113R)

CIN3+

3

43

0.31 (0.1–0.97)

0.024

 

CIN2

3

18

0.68 (0.23–2.02)

0.471

 

CIN1

2

36

0.25 (0.06-1.00)

0.023

 

CIN + total

8

97

0.36 (0.17–0.75)

0.003

 

Persistent

7

55

0.42 (0.19–0.92)

0.021

E7 prototype

CIN3+

39

7

1.20 (1.02–1.41)

0.056

 

CIN2

17

4

1.15 (0.91–1.44)

0.326

 

CIN1

33

5

1.23 (1.05–1.44)

0.042

 

CIN + total

89

16

1.20 (1.05–1.36)

0.009

 

Persistent

50

12

1.32 (1.07–1.64)

0.011

A862T (Q87L)

CIN3+

3

43

0.34 (0.11–1.07)

0.042

 

CIN2

3

18

0.75 (0.25–2.24)

0.593

 

CIN1

2

36

0.28 (0.07–1.10)

0.039

 

CIN + total

8

97

0.40 (0.19–0.84)

0.01

 

Persistent

5

57

0.32 (0.13–0.79)

0.007

E6 + E7 prototype

CIN3+

38

8

1.32 (1.11–1.58)

0.01

 

CIN2

14

7

1.07 (0.77–1.48)

0.705

 

CIN1

32

6

1.35 (1.12–1.62)

0.011

 

CIN + total

84

21

1.28 (1.10–1.50)

0.002

 

Persistent

45

17

1.35 (1.05–1.74)

0.021

  1. Note This table only shows the variants/mutations with significant statistical significance. For more detailed data, please refer to Supplementary Material 4. The results of significant differences are shown in bold. “Lesion-free” is the control “1” for the disease group, and “Non-Persistent” is the control “1” for the persistent infection ability group. “With” means carrying/belonging to the variant/mutation, while “Without” means not carrying/not belonging to the variant/mutation. The numbers under “With/Without” represent the corresponding sample numbers. “CI” stands for “Confidence Interval”. “CIN”: cervical intraepithelial neoplasia. “CIN3+” represents CIN3 and cervical cancer, and “CIN+” represents CIN and cervical cancer
Back to article page

Virology Journal

ISSN: 1743-422X